A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar ...

The pharmacy regulator is working with other bodies to jointly tackle inappropriate advertising and promotions of the drugs ...

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...

The General Pharmaceutical Council (GPhC) has introduced new rules for weight-loss jabs, such as Wegovy and Mounjaro, in ...

Amid growing concern of the overuse and misuse of obesity drugs, the UK’s pharmacies regulator rolled out stricter guidelines ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

Around half a million Britons are now thought to be using the medication, which can help them lose up to 20 per cent of their ...